Be The Match Advocates Garner $420,000+ at 2023 NY Gala for Life-Saving Blood Stem Cell Transplants
On May 4, 2023, Be The Match Foundation® hosted its annual New York Gala at the Cipriani on Broadway to raise funding for patient assistance grants, research to improve transplant outcomes, and diversification of the Be The Match Registry®. In 2022, the foundation provided $6.1 million in grants to 2,320 patients and families in need […]
Unite to Fight Blood Cancer: The Vital Role of Ethnic Minority Stem Cell Donors
In this video, Antoinette, a mother of two suffering from incurable blood cancer, shares her struggle to find a stem cell donor for nine years. She has undergone eight different types of chemotherapy, and her myeloma has spread to her spine, causing 13 spinal fractures. While a stem cell transplant won’t cure her, it would […]
Innovative Cell Therapy, Omisirge, Receives FDA Approval to Reduce Infection Risk in Blood Cancer Treatments
The FDA has approved Omisirge (omidubicel-onlv), a modified allogeneic cord blood-based cell therapy designed to speed up the recovery of neutrophils and reduce infection risk. Omisirge is intended for use in adults and pediatric patients aged 12 and older with blood cancers who are undergoing umbilical cord blood transplantation after a myeloablative conditioning regimen. Blood […]
Boosting Stem Cell Harvest: A Promising Combo Therapy Revolutionizes Transplant Success
A recent study published in the European Pharmaceutical Review has revealed that a combination therapy can significantly improve the collection of stem cells from donors. The therapy utilizes Plerixafor, a CXCR4 antagonist, in conjunction with granulocyte-colony stimulating factor (G-CSF), which helps mobilize stem cells from bone marrow to peripheral blood. The study found that this […]
Father’s Gift of Life: Young Cancer Warrior Levi Triumphs with Dad’s Stem Cell Help
7-year-old Levi Galvez celebrated being cancer-free at Riley Hospital in Indianapolis on March 27, after a five-year battle with leukemia that began when he was two years old. His father, Geovani Galvez, provided a life-saving stem cell transplant a year ago. The family celebrated the milestone with cheers, laughter, and a small ceremony. Geovani, who […]
Michael F. Price Memorial Grant from DeGregorio Family Foundation Awarded to Disrupt Cancer Stem Cells with Novel Experimental Drugs
NEW YORK, Feb. 17, 2023 /PRNewswire/ — The DeGregorio Family Foundation with support of the Esophageal Cancer Awareness Association has awarded $75,000 to Dr. Anthony Capobianco, PhD, Professor at The DeWitt Daughtry Family Department of Surgery and the Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine. The Grant is named in memory of Michael F. Price, the noted value investor and philanthropist, who […]
Helocyte, Inc. Announces Positive Data from Stem Cell Transplant Donor Vaccination Trial to be Presented at the 2023 Tandem Meetings: Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR
MIAMI, Feb. 16, 2023 (GLOBE NEWSWIRE) — Helocyte, Inc., (“Helocyte”) a subsidiary company of Fortress Biotech, Inc. (Nasdaq: FBIO), announced today that data from a Phase 1 pilot trial (see NCT03560752) evaluating the potential safety, immunological response and efficacy of the cytomegalovirus (“CMV”) vaccine Triplex to enhance CMV protective immunity in immunosuppressed recipients of allogeneic hematopoietic […]
Autologous Stem Cell Transplant: Benefits & Risks
An autologous stem cell transplant is a medical procedure that involves taking stem cells from the body of a person, processing and storing them, and then reinfusing them back into the same person’s body. This procedure has been used to treat various kinds of illnesses, including blood cancer and other diseases of the immune system. […]
Cell BioEngines Enters into an Exclusive Worldwide Agreement to Develop and Commercialize Potent Immune Cell States to Cure Cancer
BOSTON and NEW YORK, Jan. 25, 2023 (GLOBE NEWSWIRE) — Cell BioEngines Inc. (the “Company”), a cell and gene therapy company focused on developing an allogenic cell-based product for solid tumors, today announced that it has entered into an exclusive license agreement with Icahn School of Medicine at Mount Sinai (“Icahn Mount Sinai”), in New […]
ImmPACT Bio Announces FDA Clearance of IND for Novel Bispecific CAR to Treat Aggressive B-cell Lymphoma
WEST HILLS, Calif., Jan. 24, 2023 /PRNewswire/ — ImmPACT Bio USA, Inc. (“ImmPACT Bio”), a clinical-stage company developing transformative logic-gate-based chimeric antigen receptor (CAR) T-cell therapies for treating cancer, today announced clearance of its first Investigational New Drug (IND) application by the U.S. Food and Drug Administration (FDA) for IMPT-314, a bispecific “OR-Gate” autologous CAR T-cell therapy targeting the B-cell […]